Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Cassava Sciences Inc (FLNA) Price & Performance

Amphastar Pharmaceuticals IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Cassava Sciences Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.63 (market cap $868.62M), while Cassava Sciences Inc trades at $0.94 (market cap $47.75M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 18.2× Cassava Sciences Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

AMPHFLNA
Market Cap
$868.62M$47.75M
Sector
HealthHealth
52-Week High
$30.81$4.64
52-Week Low
$16.87$0.87
Enterprise Value
$1.27B-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

No Aura AI signal available yet.

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Returns comparison

Trailing returns across standard periods

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA